Camber Announces Two New Product Launches
Camber Pharmaceuticals, one of the industry’s fastest growing generic pharmaceutical companies is pleased to announce the addition of two new products to its rapidly expanding product line.
The new products are as follows:
Benztropine Mesylate Finasteride
– .5mg / 100ct – 1mg/ 30ct and 90ct
– 1mg / 100ct and 1000ct
– 2mg / 100ct and 1000ct
Camber Pharmaceuticals is a fully integrated international pharmaceutical company that maintains quality and integrity in all its products from API manufacturing to finished dosage.
Camber’s parent company Hetero Drugs of Hyderabad, India employs over 300 scientists at 9 API facilities and has a global presence in over 100 countries.
Recent articles
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
- Camber Launches Voriconazole for Injection
- Camber Launches Magnesium Sulfate Injection